Member Info for Compoundinterest

What is Bnn article? Can u share the link please? Thanks

Looks like if deal falls could go to 1p. If deal succeeds goes to 2p. IMO, what u think?

Polar Capital LLP reduced holdings was purely opportunistic to lock-in profits by selling 30p+ into the rise. However they shot themselves in the foot as now traders trying to exit at loss causing MMs to move share price to fall drastically to attract buys to fulfil the sell orders.

Polar Capital experiencing redemptions especially in the Biotech and UK fund of which hold Redx. They shot themselves in the foot cos now they have to report lower NAVs and EBITDA as share price at major discount; had they not sell this share on news, this could be sitting at 30-40p+ as free float is limited.

Polar Capital LLP reduced holdings

You have not lost until u have sold... This should come good eventually.... hopefully...fingers crossed. GL. IMO, DYOR.

Considering no news 1.8p seems a bit of a stretch.. MMs quickly moving things up on the slightly bit of buying pressure. May just hold at this range for today.GLA, IMO, DYOR.

Small Volume Massive Swing... rerate shud see this move massively if we get some good news IMO, DYOR

Looks a bit overdone to me. Could me some rebound opportunity.

Patel getting desperate.

Redx Pharma lands biggest deal to date with sale of KRAS inhibitor programme to Jazz Pharma

https://www.youtube.com/watch?v=6gQVvCXi_HM

Looks like people selling at a loss here to ride He1...

Back to 26p, same spot as a few months ago in Oct when Redx successfully raised c.£14.1 million from Redmile Biotech Fund and other new IIs. The good news still not factored into the share price imo.

Huge potential this company. Hope they turn out to be a giant like AstraZeneca or GSK a proud representative representing UK pharma and biotech.

Back in 2017, the UK biotech RedX Pharma had to sell its prized asset after administrators stepped in to stave off a debt crisis, with Loxo Oncology snapping up the BTK inhibitor for $40 million.

That drug, now known as LOXO-305 was one of the stars of the American Society of Haematology (ASH) conference in December, finding its way into Eli Lilly’s pipeline after the big pharma’s $8 billion takeover of Loxo.

https://pharmaphorum.com/news/redx-looks-to-keep-pipeline-assets-after

I like this "Our last published valuation was £367m/$441m, or 94p per share, which does not include this latest KRAS deal with Jazz." A 3x bagger according to their target price. Onwards and upwards. 🔥

Needs to come down a bit in order to go up. Give everyone chance to fill their boots. 🔥

Intraday RSI back down to 50 from 90... from overbought to neutral indicating there could be more space to go up after those short-term traders sold out on small profit.

Just the beginning. The profit lock-in traders selling at 29p very quickly will regret it it gets absorbed reflecting in the share price. 🔥 🔥 🔥 Redx onwards and upwards. DYOR, IMO

ST Traders profit taking. Taking a breather and then ready for more 🔥 🔥 🔥 DYOR, IMO

Redmile US Biotech Hedgefund owns 72% of this company.. as well as other IIs totalling 95% owned by institutional investors. Free float less than 5%... no wonder going to NT to buy. Not enough supply to meet demand currently. Share price responding to the amazing news. DYOR, IMO

Funds Managed by Redmile Group, LLC - 71.18%

Sofinnova Crossover I SLP 13.35%

Polar Capital LLP 6.25%

Invus Public Equities L.P 3.91%

NT to buy... limited supply. Demand exceeding supply massively which should help with the share price. IMO, DYOR.